PRIVATE BETA — FOUNDER ACCESS ONLY/INVESTORS PERMANENTLY EXCLUDED/VERIFIED FOUNDERS ONLY/PRIVATE BETA — FOUNDER ACCESS ONLY/INVESTORS PERMANENTLY EXCLUDED/VERIFIED FOUNDERS ONLY/PRIVATE BETA — FOUNDER ACCESS ONLY/INVESTORS PERMANENTLY EXCLUDED/VERIFIED FOUNDERS ONLY/PRIVATE BETA — FOUNDER ACCESS ONLY/INVESTORS PERMANENTLY EXCLUDED/VERIFIED FOUNDERS ONLY/PRIVATE BETA — FOUNDER ACCESS ONLY/INVESTORS PERMANENTLY EXCLUDED/VERIFIED FOUNDERS ONLY/PRIVATE BETA — FOUNDER ACCESS ONLY/INVESTORS PERMANENTLY EXCLUDED/VERIFIED FOUNDERS ONLY/PRIVATE BETA — FOUNDER ACCESS ONLY/INVESTORS PERMANENTLY EXCLUDED/VERIFIED FOUNDERS ONLY/PRIVATE BETA — FOUNDER ACCESS ONLY/INVESTORS PERMANENTLY EXCLUDED/VERIFIED FOUNDERS ONLY/
← Fund Intelligence
DOSSIER // VERIFIED INTEL

Euclidean Capital

New York, NYEUCLIDEAN-CAPITAL
0
Truth Cards
0
Partners Rated
Avg Score
Get Access
Access Level
◈ Truth Cards
0 VERIFIED

No verified intel yet.
Be the first founder to leave a truth card.

Request Founder Access →
Dossier Summary

Jim Simons' family office making technology and science-focused venture investments.

Classification
Slugeuclidean-capital
HQNew York, NY
Stage FocusEuclidean Capital has made 10 investments in Series B sta…
Intel StatusAccepting submissions
🔥 BERNIE'S HOT TAKE

This isn't your typical family office - it's Renaissance Technologies with a venture capital arm. Euclidean Capital serves as a family office of James Simons who is a hedge fund manager, mathematician, and founder of Renaissance Technologies. The stocks represent just a small part of Euclidean's portfolio - most are 'residuals' from VC investments they held onto after IPO. They're essentially doing quantitative venture capital before anyone called it that. The team is small but incredibly sophisticated - Chhabra pioneered goals-based wealth management and Miller has deep quant experience. They write big checks ($50M+ rounds) and focus on math-heavy sectors where their analytical edge matters most. Don't expect warm fuzzy founder support - this is clinical, data-driven capital.

KEY TAKEAWAYS
  • Best for: Deep-tech startups needing sophisticated capital and quantitative due diligence
  • Watch out for: Very analytical approach - not your hand-holding, mentor-type investors
  • Known for: Writing large checks in AI/biotech with Renaissance-level analytical rigor
Investment Thesis

This family office focuses on private capital, investing in early-stage companies with high growth potential. It has previously invested in AI & Biotech companies. Euclidean essentially does quantitative venture capital, applying the same data-driven approach that made Renaissance Technologies legendary.

Stage & Sector Focus

Euclidean Capital has made 10 investments in Series B stage with an average round size of $75.6M, 9 investments in Series A stage with an average round size of $57M and 5 investments in Series C stage with an average round size of $65.6M. They focus heavily on life sciences/biotech, AI/machine learning, and healthcare tech - basically betting on algorithms and molecules, which makes sense given Jim Simons' background.

Notable Portfolio
ASAPP23andMeCircle PharmaPMV PharmaAlectorRAPT TherapeuticsCodagenixPeltarion
Key Partners
Ashvin Chhabra
President & Chief Investment Officer

Dr. Chhabra was Chief Investment Officer and head of investment management and guidance at Merrill Lynch Wealth Management from 2013-2015. He was the Chief Investment Officer at the Institute for Advanced Study from 2007-2013. He is widely recognized as one of the founders of goals based wealth management and for his seminal work "Beyond Markowitz" which integrates Modern Portfolio Theory with Behavioral Finance.

Monique Miller
Head of Investment Strategy

Monique Miller, a former managing director at Wilshire, joined Euclidean as its head of investment strategy in 2018. She oversees investment strategy, process and governance. Her responsibilities also extend to co-managing Euclidean's hedge fund portfolio. Has deep quant fund experience from Caxton Associates.

Have a specific question about Euclidean Capital?

Ask Bernie →
INVESTOR ACCESS PERMANENTLY DENIEDBERNBOOK // DOSSIER v1